Pharmacy

Top Medical News
High-dose PPI use among cirrhotic patients poses risk of death, complications
10 hours ago
Patients with cirrhosis who are exposed to high-dose proton pump inhibitors (PPIs) are at increased risk of death and cirrhotic complications, as suggested in a retrospective study.
Patient-reported outcomes in advanced RCC favour belzutifan over everolimus
Jairia Dela Cruz, 14 hours ago
Treatment with belzutifan helps patients with previously treated advanced renal cell carcinoma (RCC) achieve better disease-specific symptoms and quality of life (QoL) compared with everolimus, according to the patient-reported outcome (PRO) data from the phase III LITESPARK-005 trial.
COVID-19 vaccine–related cycle length changes linked to receipt of vaccine during follicular phase
22 hours ago
Receipt of the COVID-19 vaccine during the follicular phase of the menstrual cycle leads to changes in cycle length, as reported in a study.
Subcutaneous noninferior to intravenous nivolumab for clear cell renal cell carcinoma
Jairia Dela Cruz, Yesterday
Subcutaneous nivolumab is good enough for patients with previously treated advanced or metastatic clear cell renal cell carcinoma (ccRCC) when compared with intravenous nivolumab, with no significant differences in the pharmacokinetic, efficacy, and safety endpoints, according to data from the open-label, phase III CheckMate 67T study.
Semaglutide induces weight loss despite antidepressant use
Stephen Padilla, Yesterday
Treatment with semaglutide 2.4 mg results in clinically meaningful weight loss, irrespective of baseline antidepressant (AD) use, among adults with overweight/obesity, reports a post hoc study of the Semaglutide Treatment Effect for People with obesity (STEP).
Trastuzumab deruxtecan shows promise in metastatic breast cancer
Yesterday
Treatment with trastuzumab deruxtecan (T-DXd) provides sustained antitumour activity and shows a consistent safety profile in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (mBC) previously treated with trastuzumab emtansine (T-DM1), as shown by the updated survival results from the phase II DESTINY-Breast01 trial.
Denosumab for osteoporosis shows potential for lowering diabetes risk
Jairia Dela Cruz, 2 days ago
Treatment with denosumab in people with osteoporosis confers a protective effect against the risk of developing diabetes, according to the results of a propensity score–matched cohort study from Taiwan.
Special Reports
Nicorette® QuickMist Launch Symposium
19 Jan 2024
During the launch of Nicorette® QuickMist at the Kuala Lumpur Nicotine Addiction International Conference (KLNAC) 2023, a panel of distinguished experts led the discussion on the role of Nicotine Replacement Therapy (NRT) on smoking cessation management. The panel comprised of notable experts, including Professor Chris Bullen (New Zealand), Associate Professor Dr Amer Siddiq bin Amer Nordin (Malaysia), Dr Philip Tønnesen (Denmark) and Professor Philip Eng (Singapore).
COVID-19, nirmatrelvir, ritonavir, mRNA vaccine, Omicron, COPD, CDC, WHO
Dr. Chan Kwok Wai Adrian, Prof. Yang Kuang-Yao, 10 Jan 2024
At the 27th Congress of the Asian Pacific Society of Respirology (APSR) 2023, a Pfizer-sponsored symposium addressed the evolving challenges of COVID-19, particularly for patients with pre-existing respiratory conditions. Chaired by Dr Chan Kwok Wai Adrian, a renowned respiratory physician and intensivist from Mount Elizabeth Novena Hospital, Singapore, and featuring insights from Professor Yang Kuang-Yao of National Yang Ming Chiao Tung University, Taipei, Taiwan, the symposium focused on the disease’s impact, treatment guidelines, regional management strategies, and the role of nirmatrelvir/ritonavir, a new oral combination pill, in the treatment of COVID-19.
Navigating invasive fungal infections in unconventional hosts — insights and strategies
Assoc Prof. Carolina García-Vidal, Dr. Jasmine Chung, 06 Jan 2024

At a recent symposium organized by Pfizer, in collaboration with the Society of Infectious Disease Singapore, A/Prof Carolina García-Vidal, Senior Specialist, Infectious Diseases Department at Hospital Clínic de Barcelona, Spain, shared valuable insights on managing invasive fungal infections (IFIs) in nontraditional hosts. The session was chaired by Dr Jasmine Chung, Senior Consultant and Director of the Antimicrobial Stewardship Unit, Singapore General Hospital.

Product Highlight - MENQUADFI
28 Dec 2023
Meningococcal group A, C, W & Y conjugate vaccine 0.5 mL solution for injection
Breaking ground in migraine management: First Consensus Guidelines from the Headache Society of Singapore
06 Dec 2023
In a pioneering effort, the Headache Society of Singapore (HSS) has released the first edition of consensus guidelines focusing on the approach to headache disorders and management of migraine. Amid a rapidly growing array of therapeutic options, standardizing treatment approaches is crucial. These guidelines provide a pivotal resource for healthcare professionals navigating the complex landscape of headache disorders, with a special focus on migraine management in adults.
A closer look at ceftazidime-avibactam in real-world settings
07 Nov 2023

Antibiotic misuse and overuse fuel mutations in bacteria, leading to drug-resistant “superbugs,” with terrifying aftermath. Without intervention, antimicrobial resistance could cause 10 million deaths annually by 2050.

Every year, from November 18–24, the World Antimicrobial Awareness Week highlights these risks and promotes innovative treatments, enhanced surveillance, and best-practice sharing among clinicians. This article offers insights on the use of the fixed-dose combination antibiotic ceftazidime-avibactam in daily hospital settings.

New study unlocks rimegepant benefits for acute migraine
06 Nov 2023

A landmark study conducted in China and South Korea has demonstrated the effectiveness and safety of rimegepant – a groundbreaking orally administered calcitonin gene-related peptide (CGRP) antagonist – for the acute treatment of migraine among adults. [Lancet Neurol 2023;22:476-484] This phase III, double-blind, randomized, placebo-controlled trial marks the first clinical study of a gepant for migraine in China and South Korea, offering promising insights into migraine management.

Conference Reports
Subcutaneous noninferior to intravenous nivolumab for clear cell renal cell carcinoma
Jairia Dela Cruz, 03 Mar 2024
Subcutaneous nivolumab is good enough for patients with previously treated advanced or metastatic clear cell renal cell carcinoma (ccRCC) when compared with intravenous nivolumab, with no significant differences in the pharmacokinetic, efficacy, and safety endpoints, according to data from the open-label, phase III CheckMate 67T study.
CheckMate 9ER: Nivolumab + cabozantinib maintains survival benefit, response in aRCC
Elaine Soliven, 02 Mar 2024

The combination therapy of nivolumab plus cabozantinib (NIVO + CABO) continues to show long-term survival benefits and response rates over sunitinib at 55 months in patients with previously untreated advanced renal cell carcinoma (aRCC), according to updated results of the CheckMate 9ER study presented at ASCO GU 2024.

Nivolumab plus ipilimumab superior to sunitinib in advanced RCC
Stephen Padilla, 01 Mar 2024
First-line treatment with nivolumab plus ipilimumab (NIVO+IPI) results in better survival and response benefits in patients with advanced renal cell carcinoma (aRCC) when compared with sunitinib (SUN), as shown by long-term follow-up data from the CheckMate 214 trial.
Pembrolizumab plus lenvatinib effective against nonclear cell RCC
Stephen Padilla, 29 Feb 2024
Pembrolizumab (pembro) plus lenvatinib (lenva) provides durable antitumour activity in patients with advanced nonclear cell renal cell carcinoma (nccRCC) and has a manageable safety profile, according to the results of the phase II KEYNOTE-B61 study.
TKI-ICI combo offers hope for prostate cancer patients with poor prognosis
Audrey Abella, 29 Feb 2024
A combination of the TKI* cabozantinib and ICI** atezolizumab improved progression-free survival (PFS) in men with metastatic castration-resistant prostate cancer (mCRPC) with measurable extrapelvic nodal or visceral metastasis who progressed on prior novel hormonal therapy (NHT), findings from the phase III CONTACT-02 trial have shown.
Adjuvant pembrolizumab holds promise in bladder cancer
Audrey Abella, 28 Feb 2024
The phase III AMBASSADOR Alliance A031501 trial showed a statistically significant and clinically meaningful improvement in disease-free survival (DFS) with adjuvant pembrolizumab compared with observation in patients with high-risk locally advanced muscle-invasive urothelial carcinoma (MIUC) after radical surgery regardless of PD-L1 status.
KEYNOTE-564: Adjuvant pembrolizumab ups survival in kidney cancer
Elaine Soliven, 28 Feb 2024

Adjuvant treatment with pembrolizumab has significantly improved overall survival (OS) in patients with clear cell renal cell carcinoma (RCC) who are at high risk of recurrence after surgery, according to an updated analysis of the KEYNOTE-564 trial presented at ASCO GU 2024.